Drug Formulary Review Archives – December 1, 2002
December 1, 2002
View Issues
-
FDA proposal could increase generics, but critics say they’ve seen it before
A new Food and Drug Administration (FDA) proposed rule is designed to speed up the availability of generic drugs and reduce costs for consumers. -
Health plan finds success with its generic coupon
Last December, Blue Cross Blue Shield of Michigan (BCBSM) in Detroit mailed coupons to about 7,000 member homes. These coupons waived the copayment when members tried a generic version of a brand-name drug for the first time. -
Medical center turns to automated drug dispensing
In an effort to reduce medical errors and comply with patient safety standards, one Georgia medical center has turned to automation. -
News Briefs
FDA approves generic omeprazole; Study says schools often stray from set guidelines; Warnings strengthened by urokinase reintroduction; Complications related to bone cement, FDA says; In the year 2020: Shortfall of even more pharmacists. -
New FDA Approvals
New FDA Approvals -
Drug Criteria & Outcomes: Drug evaluation: Caspofungin for IV infusion
Caspofungin acetate is a sterile, lyophilized, semisynthetic product for IV infusion. It is available as a hygroscopic white to off-white powder and is freely soluble in water and methanol, and slightly soluble in ethanol. -
Drug Criteria & Outcomes: Neuroleptic Malignant Syndrome: An overview
Neuroleptic malignant syndrome (NMS) is a rare but life-threatening adverse effect that is associated with neuroleptic drugs, primarily the phenothiazines. NMS has occurred with even the less potent phenothiazines that are used to treat nausea, such as promethazine. -
Drug Criteria & Outcomes: In the Pipeline
In the Pipeline